Marion Wealth Management Buys 2,633 Shares of Eli Lilly and Company (NYSE:LLY)

Marion Wealth Management raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 492.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,168 shares of the company's stock after purchasing an additional 2,633 shares during the quarter. Marion Wealth Management's holdings in Eli Lilly and Company were worth $2,617,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Knightsbridge Asset Management LLC boosted its holdings in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares in the last quarter. Centerpoint Advisory Group acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $514,000. Kentucky Trust Co acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $834,000. CSM Advisors LLC raised its position in Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares in the last quarter. Finally, Proficio Capital Partners LLC raised its position in Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after purchasing an additional 1,562 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $15.76 during trading on Friday, hitting $738.33. 6,102,436 shares of the stock were exchanged, compared to its average volume of 3,639,718. The stock has a market capitalization of $699.74 billion, a price-to-earnings ratio of 63.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a fifty day moving average price of $776.85 and a 200-day moving average price of $799.88. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Analysts Set New Price Targets

Several brokerages have weighed in on LLY. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Finally, Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.